

Date: September 9, 2025

Dear Health Care Provider:

**Re: Manitoba RSV Prophylaxis Program for 2025-2026 Season**

The details for the 2025-2026 Season of the Manitoba RSV Prophylaxis Program are below:

**Product Used for 2025-26 Season**

The Manitoba RSV Prophylaxis Program will use nirsevimab (Beyfortus®) for the 2025-26 season. This is a long-acting monoclonal antibody. Only one dose is required to provide protection against respiratory syncytial virus for up to 6 months.

**Eligibility for Nirsevimab**

There are two aspects to this year's program. The Public Health Program will offer nirsevimab (Beyfortus®) to **all** infants born from October 1, 2025 to March 31, 2026. Dosing will be provided before discharge home or as outpatient by public health nurses, midwives, or at outpatient clinics organized by Public Health.

The Manitoba High-Risk RSV Prophylaxis Program will follow and provide doses to infants and children who meet the high-risk eligibility criteria (see page 2).

**Start Date and Dosing:**

The RSV prophylaxis season will start on **October 1, 2025**. That will be the first day of nirsevimab (Beyfortus®) injections for both inpatients and outpatients. For newborns, dosing should be given just before discharge. Unlike past seasons, dosing can be provided any day of the week. Dose is based on weight with nirsevimab (Beyfortus®) dispensed a prefilled single-use syringe (see page 2)

**Approval Process:**

No prior approval is required for infants born from October 1, 2025 to March 31, 2026. However, if an infant also meet any high-risk eligibility criteria, please do complete a Patient Referral Form and fax to our office for review before dosing. A copy of the referral form is attached. Please make copies and fax your completed referral form to the MB RSVP Office at (204) 940-1346.

**Residents of Other Provinces and Territory:**

Public Health is offering Beyfortus® (nirsevimab) to any infant in Manitoba who meets any eligibility criteria, regardless of which province or territory the infant is from originally or will reside permanently.

## **Manitoba's RSV Prophylaxis Eligibility Criteria 2025-2026 Season**

### **Public Health Program:**

Any infant **born from October 1, 2025 to March 31, 2026 is eligible automatically**. No approval from Manitoba High-Risk Prophylaxis Program is needed. If infant also meet the high-risk eligibility criteria below, please complete this form and contact the Manitoba High-Risk Prophylaxis Program.

### **High-Risk Eligibility Criteria:**

1. Premature infants born < 33 weeks gestational age and born after April 1, 2025
2. Children < 24 months of age as of October 1, 2025 with chronic lung disease due to prematurity (i.e. BPD) and who have received oxygen therapy recently.
3. Children < 24 months of age as of October 1, 2025 with hemodynamically significant heart disease as assessed by paediatric cardiology. Referral should be made through Paediatric Cardiology
4. Other children < 24 months of age as of October 1, 2025 may be considered on an individual basis. Such referrals will require a letter of support from the paediatrician/family physician and from a paediatric subspecialist (typically Respiriology, Infectious Disease, Cardiology, Genetics or Haematology/ Oncology). Contact the MB RSVP Office at (204) 787-2535 to discuss potential eligibility

For infants meeting any high-risk eligibility criteria, prior approval from the Manitoba High-Risk RSV Prophylaxis Program is required before giving Beyfortus® (nirsevimab).

### **Nirsevimab (Beyfortus®) Dosing:**

- Nirsevimab should be given on day of discharge or within days of planned discharge
- Infant's current weight must be greater than 1.6 kg.
- Dosing is based on the greater of birth weight or current weight:
  - < **5.0 kg**: give 50 mg IM as a single 50 mg/0.5mL prefilled syringe
  - ≥ **5.0 kg and < 10 kg**: give 100 mg IM as a single 100 mg/1.0mL prefilled syringe
  - ≥ **10 kg**: give 200 mg IM as 2 x 100 mg/1.0mL prefilled syringes, given at two different sites

---

### **How to Contact Us**

Please contact us if there are any questions about the Manitoba High-Risk RSV Prophylaxis Program. Our office is located at the Manitoba Clinic:

Manitoba High-Risk RSV Prophylaxis Program  
Manitoba Clinic 8<sup>th</sup> Floor  
790 Sherbrook Street  
Winnipeg, MB R3A 1M3  
Phone: (204) 787-2535  
Fax: (204) 940-1346  
E-mail address is: [rsvprogram@exchange.hsc.mb.ca](mailto:rsvprogram@exchange.hsc.mb.ca)

Sincerely,



Dr. Aaron Chiu  
Medical Director - Manitoba RSV Prophylaxis Program  
Associate Professor of Pediatrics  
Section of Neonatology  
University of Manitoba